DCGI Gives Nod To AstraZeneca Pharma India To Import, Market Selumetinib Capsules

Drug firm AstraZeneca Pharma India has received import and market permission from the Indian drug regulator for Selumetinib capsules.

Drug firm AstraZeneca Pharma India has received import and market permission from the Indian drug regulator for Selumetinib capsules.

AstraZeneca Pharma India said in a regulatory filing, the company has received import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules.

The permission receipt paves way for the launch of Selumetinib 10 mg & 25 mg capsules

in India, subject to the receipt of related statutory approvals and licenses, it added.

Selumetinib 10 mg & 25 mg capsules are indicated for the treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country. The new phase of universalization of COVID-19 vaccination commenced on 21st June 2021. The vaccination drive has been ramped up through the availability of more vaccines, advanced visibility of vaccine availability to States and UTs for enabling better planning by them and streamlining the vaccine supply chain.

As part of the nationwide vaccination drive, the Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.

Facebook Comments